APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Genetic Screening for Carrier Diseases

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Genetic Screening for Carrier Diseases Market Outlook and Growth Opportunities 2026

Report ID 17414903041 January 2026217 pages

Choose your research edition.

Industry ResearchGenetic Screening for Carrier Diseases Industry Research Report 2026139 pages · $2,950 USDIndustry Growth & TrendsGlobal Genetic Screening for Carrier Diseases Industry Growth and Trends Forecast to 2032123 pages · $3,450 USDMarket StructureGlobal Genetic Screening for Carrier Diseases Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Genetic Screening for Carrier Diseases Market Outlook and Growth Opportunities 2026217 pages · $4,250 USDMarket Analysis & ForecastGlobal Genetic Screening for Carrier Diseases Market Analysis and Forecast 2026-2032213 pages · $4,950 USD

Market perspective

The global Genetic Screening for Carrier Diseases market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Genetic Screening for Carrier Diseases is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Genetic Screening for Carrier Diseases is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Genetic Screening for Carrier Diseases is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Genetic Screening for Carrier Diseases market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Genetic Screening for Carrier Diseases market include Thermo Fisher Scientific, Eurofins Scientific, Illumina, Invitae, MedGenome, Myriad Genetics, Roche, Natera and OPKO Health, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Genetic Screening for Carrier Diseases market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Genetic Screening for Carrier Diseases and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Genetic Screening for Carrier Diseases revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Genetic Screening for Carrier Diseases market.

Genetic Screening for Carrier Diseases Segment by Company

Thermo Fisher Scientific

Eurofins Scientific

Illumina

Invitae

MedGenome

Myriad Genetics

Roche

Natera

OPKO Health

23andMe

bioMérieux

EKF Diagnostics

Gene by Gene (myDNA)

Fulgent Genetics

NxGen MDx

Sonic Genetics

My Baby

AncestryDNA

DiaSorin

Grifols

BGI Genomics

Chigene

Jiajian Medical Testing

Genesky

Berry Genomics

Weihansi Biomedical Technology

Annaroad

Genetic Screening for Carrier Diseases Segment by Type

NGS

Whole Exome Sequencing

Others

Genetic Screening for Carrier Diseases Segment by Application

Couple

Individual

Genetic Screening for Carrier Diseases Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Genetic Screening for Carrier Diseases status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Genetic Screening for Carrier Diseases key companies, revenue, market share, and recent developments.

3. To split the Genetic Screening for Carrier Diseases breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Genetic Screening for Carrier Diseases market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Genetic Screening for Carrier Diseases significant trends, drivers, influence factors in global and regions.

6. To analyze Genetic Screening for Carrier Diseases competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Genetic Screening for Carrier Diseases market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Genetic Screening for Carrier Diseases and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Genetic Screening for Carrier Diseases.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Genetic Screening for Carrier Diseases industry.

Chapter 3: Detailed analysis of Genetic Screening for Carrier Diseases company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Genetic Screening for Carrier Diseases in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Genetic Screening for Carrier Diseases in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Genetic Screening for Carrier Diseases Industry Trends Table 2. Genetic Screening for Carrier Diseases Industry Drivers Table 3. Genetic Screening for Carrier Diseases Industry Opportunities and Challenges Table 4. Genetic Screening for Carrier Diseases Industry Restraints Table 5. Global Genetic Screening for Carrier Diseases Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Genetic Screening for Carrier Diseases Revenue Share by Company (2021-2026) Table 7. Global Genetic Screening for Carrier Diseases Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Genetic Screening for Carrier Diseases Key Company Manufacturing Base & Headquarters Table 9. Global Genetic Screening for Carrier Diseases Company, Product Type & Application Table 10. Global Genetic Screening for Carrier Diseases Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Genetic Screening for Carrier Diseases by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of NGS Table 15. Significant Companies of Whole Exome Sequencing Table 16. Significant Companies of Others Table 17. Global Genetic Screening for Carrier Diseases Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Genetic Screening for Carrier Diseases Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Genetic Screening for Carrier Diseases Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Genetic Screening for Carrier Diseases Sales Value Share by Type (2021-2026) Table 21. Global Genetic Screening for Carrier Diseases Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Couple Table 23. Significant Companies of Individual Table 24. Global Genetic Screening for Carrier Diseases Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Genetic Screening for Carrier Diseases Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global Genetic Screening for Carrier Diseases Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global Genetic Screening for Carrier Diseases Sales Value Share by Application (2021-2026) Table 28. Global Genetic Screening for Carrier Diseases Sales Value Share by Application (2027-2032) Table 29. Global Genetic Screening for Carrier Diseases Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Genetic Screening for Carrier Diseases Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global Genetic Screening for Carrier Diseases Sales Value Share by Region (2021-2026) Table 32. Global Genetic Screening for Carrier Diseases Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global Genetic Screening for Carrier Diseases Sales Value Share by Region (2027-2032) Table 34. Global Genetic Screening for Carrier Diseases Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Genetic Screening for Carrier Diseases Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global Genetic Screening for Carrier Diseases Sales Value Market Share by Country (2021-2026) Table 37. Global Genetic Screening for Carrier Diseases Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global Genetic Screening for Carrier Diseases Sales Value Market Share by Country (2027-2032) Table 39. Thermo Fisher Scientific Company Information Table 40. Thermo Fisher Scientific Business Overview Table 41. Thermo Fisher Scientific Genetic Screening for Carrier Diseases Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. Thermo Fisher Scientific Genetic Screening for Carrier Diseases Product Portfolio Table 43. Thermo Fisher Scientific Recent Development Table 44. Eurofins Scientific Company Information Table 45. Eurofins Scientific Business Overview Table 46. Eurofins Scientific Genetic Screening for Carrier Diseases Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Eurofins Scientific Genetic Screening for Carrier Diseases Product Portfolio Table 48. Eurofins Scientific Recent Development Table 49. Illumina Company Information Table 50. Illumina Business Overview Table 51. Illumina Genetic Screening for Carrier Diseases Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Illumina Genetic Screening for Carrier Diseases Product Portfolio Table 53. Illumina Recent Development Table 54. Invitae Company Information Table 55. Invitae Business Overview Table 56. Invitae Genetic Screening for Carrier Diseases Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Invitae Genetic Screening for Carrier Diseases Product Portfolio Table 58. Invitae Recent Development Table 59. MedGenome Company Information Table 60. MedGenome Business Overview Table 61. MedGenome Genetic Screening for Carrier Diseases Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. MedGenome Genetic Screening for Carrier Diseases Product Portfolio Table 63. MedGenome Recent Development Table 64. Myriad Genetics Company Information Table 65. Myriad Genetics Business Overview Table 66. Myriad Genetics Genetic Screening for Carrier Diseases Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Myriad Genetics Genetic Screening for Carrier Diseases Product Portfolio Table 68. Myriad Genetics Recent Development Table 69. Roche Company Information Table 70. Roche Business Overview Table 71. Roche Genetic Screening for Carrier Diseases Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Roche Genetic Screening for Carrier Diseases Product Portfolio Table 73. Roche Recent Development Table 74. Natera Company Information Table 75. Natera Business Overview Table 76. Natera Genetic Screening for Carrier Diseases Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Natera Genetic Screening for Carrier Diseases Product Portfolio Table 78. Natera Recent Development Table 79. OPKO Health Company Information Table 80. OPKO Health Business Overview Table 81. OPKO Health Genetic Screening for Carrier Diseases Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. OPKO Health Genetic Screening for Carrier Diseases Product Portfolio Table 83. OPKO Health Recent Development Table 84. 23andMe Company Information Table 85. 23andMe Business Overview Table 86. 23andMe Genetic Screening for Carrier Diseases Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. 23andMe Genetic Screening for Carrier Diseases Product Portfolio Table 88. 23andMe Recent Development Table 89. bioMérieux Company Information Table 90. bioMérieux Business Overview Table 91. bioMérieux Genetic Screening for Carrier Diseases Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. bioMérieux Genetic Screening for Carrier Diseases Product Portfolio Table 93. bioMérieux Recent Development Table 94. EKF Diagnostics Company Information Table 95. EKF Diagnostics Business Overview Table 96. EKF Diagnostics Genetic Screening for Carrier Diseases Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. EKF Diagnostics Genetic Screening for Carrier Diseases Product Portfolio Table 98. EKF Diagnostics Recent Development Table 99. Gene by Gene (myDNA) Company Information Table 100. Gene by Gene (myDNA) Business Overview Table 101. Gene by Gene (myDNA) Genetic Screening for Carrier Diseases Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Gene by Gene (myDNA) Genetic Screening for Carrier Diseases Product Portfolio Table 103. Gene by Gene (myDNA) Recent Development Table 104. Fulgent Genetics Company Information Table 105. Fulgent Genetics Business Overview Table 106. Fulgent Genetics Genetic Screening for Carrier Diseases Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Fulgent Genetics Genetic Screening for Carrier Diseases Product Portfolio Table 108. Fulgent Genetics Recent Development Table 109. NxGen MDx Company Information Table 110. NxGen MDx Business Overview Table 111. NxGen MDx Genetic Screening for Carrier Diseases Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. NxGen MDx Genetic Screening for Carrier Diseases Product Portfolio Table 113. NxGen MDx Recent Development Table 114. Sonic Genetics Company Information Table 115. Sonic Genetics Business Overview Table 116. Sonic Genetics Genetic Screening for Carrier Diseases Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. Sonic Genetics Genetic Screening for Carrier Diseases Product Portfolio Table 118. Sonic Genetics Recent Development Table 119. My Baby Company Information Table 120. My Baby Business Overview Table 121. My Baby Genetic Screening for Carrier Diseases Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 122. My Baby Genetic Screening for Carrier Diseases Product Portfolio Table 123. My Baby Recent Development Table 124. AncestryDNA Company Information Table 125. AncestryDNA Business Overview Table 126. AncestryDNA Genetic Screening for Carrier Diseases Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 127. AncestryDNA Genetic Screening for Carrier Diseases Product Portfolio Table 128. AncestryDNA Recent Development Table 129. DiaSorin Company Information Table 130. DiaSorin Business Overview Table 131. DiaSorin Genetic Screening for Carrier Diseases Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 132. DiaSorin Genetic Screening for Carrier Diseases Product Portfolio Table 133. DiaSorin Recent Development Table 134. Grifols Company Information Table 135. Grifols Business Overview Table 136. Grifols Genetic Screening for Carrier Diseases Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 137. Grifols Genetic Screening for Carrier Diseases Product Portfolio Table 138. Grifols Recent Development Table 139. BGI Genomics Company Information Table 140. BGI Genomics Business Overview Table 141. BGI Genomics Genetic Screening for Carrier Diseases Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 142. BGI Genomics Genetic Screening for Carrier Diseases Product Portfolio Table 143. BGI Genomics Recent Development Table 144. Chigene Company Information Table 145. Chigene Business Overview Table 146. Chigene Genetic Screening for Carrier Diseases Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 147. Chigene Genetic Screening for Carrier Diseases Product Portfolio Table 148. Chigene Recent Development Table 149. Jiajian Medical Testing Company Information Table 150. Jiajian Medical Testing Business Overview Table 151. Jiajian Medical Testing Genetic Screening for Carrier Diseases Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 152. Jiajian Medical Testing Genetic Screening for Carrier Diseases Product Portfolio Table 153. Jiajian Medical Testing Recent Development Table 154. Genesky Company Information Table 155. Genesky Business Overview Table 156. Genesky Genetic Screening for Carrier Diseases Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 157. Genesky Genetic Screening for Carrier Diseases Product Portfolio Table 158. Genesky Recent Development Table 159. Berry Genomics Company Information Table 160. Berry Genomics Business Overview Table 161. Berry Genomics Genetic Screening for Carrier Diseases Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 162. Berry Genomics Genetic Screening for Carrier Diseases Product Portfolio Table 163. Berry Genomics Recent Development Table 164. Weihansi Biomedical Technology Company Information Table 165. Weihansi Biomedical Technology Business Overview Table 166. Weihansi Biomedical Technology Genetic Screening for Carrier Diseases Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 167. Weihansi Biomedical Technology Genetic Screening for Carrier Diseases Product Portfolio Table 168. Weihansi Biomedical Technology Recent Development Table 169. Annaroad Company Information Table 170. Annaroad Business Overview Table 171. Annaroad Genetic Screening for Carrier Diseases Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 172. Annaroad Genetic Screening for Carrier Diseases Product Portfolio Table 173. Annaroad Recent Development Table 174. Research Programs/Design for This Report Table 175. Authors List of This Report Table 176. Secondary Sources Table 177. Primary Sources List of Figures Figure 1. Genetic Screening for Carrier Diseases Product Image Figure 2. Global Genetic Screening for Carrier Diseases Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Genetic Screening for Carrier Diseases Market Size (2021-2032) & (US$ Million) Figure 4. Global Genetic Screening for Carrier Diseases Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. NGS Image Figure 8. Whole Exome Sequencing Image Figure 9. Others Image Figure 10. Global Genetic Screening for Carrier Diseases Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Genetic Screening for Carrier Diseases Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Genetic Screening for Carrier Diseases Sales Value Share by Type (2021-2032) Figure 13. Couple Image Figure 14. Individual Image Figure 15. Global Genetic Screening for Carrier Diseases Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Genetic Screening for Carrier Diseases Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Genetic Screening for Carrier Diseases Sales Value Share by Application (2021-2032) Figure 18. Global Genetic Screening for Carrier Diseases Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Genetic Screening for Carrier Diseases Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America Genetic Screening for Carrier Diseases Sales Value (2021-2032) & (US$ Million) Figure 21. North America Genetic Screening for Carrier Diseases Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe Genetic Screening for Carrier Diseases Sales Value (2021-2032) & (US$ Million) Figure 23. Europe Genetic Screening for Carrier Diseases Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific Genetic Screening for Carrier Diseases Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific Genetic Screening for Carrier Diseases Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America Genetic Screening for Carrier Diseases Sales Value (2021-2032) & (US$ Million) Figure 27. South America Genetic Screening for Carrier Diseases Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa Genetic Screening for Carrier Diseases Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa Genetic Screening for Carrier Diseases Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA Genetic Screening for Carrier Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA Genetic Screening for Carrier Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA Genetic Screening for Carrier Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada Genetic Screening for Carrier Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada Genetic Screening for Carrier Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada Genetic Screening for Carrier Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico Genetic Screening for Carrier Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico Genetic Screening for Carrier Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico Genetic Screening for Carrier Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany Genetic Screening for Carrier Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany Genetic Screening for Carrier Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany Genetic Screening for Carrier Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France Genetic Screening for Carrier Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France Genetic Screening for Carrier Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France Genetic Screening for Carrier Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. Genetic Screening for Carrier Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. Genetic Screening for Carrier Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. Genetic Screening for Carrier Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy Genetic Screening for Carrier Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy Genetic Screening for Carrier Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy Genetic Screening for Carrier Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain Genetic Screening for Carrier Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain Genetic Screening for Carrier Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain Genetic Screening for Carrier Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia Genetic Screening for Carrier Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia Genetic Screening for Carrier Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia Genetic Screening for Carrier Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands Genetic Screening for Carrier Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands Genetic Screening for Carrier Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands Genetic Screening for Carrier Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries Genetic Screening for Carrier Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries Genetic Screening for Carrier Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries Genetic Screening for Carrier Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China Genetic Screening for Carrier Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China Genetic Screening for Carrier Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China Genetic Screening for Carrier Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan Genetic Screening for Carrier Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan Genetic Screening for Carrier Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan Genetic Screening for Carrier Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea Genetic Screening for Carrier Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea Genetic Screening for Carrier Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea Genetic Screening for Carrier Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India Genetic Screening for Carrier Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India Genetic Screening for Carrier Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India Genetic Screening for Carrier Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia Genetic Screening for Carrier Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia Genetic Screening for Carrier Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia Genetic Screening for Carrier Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia Genetic Screening for Carrier Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia Genetic Screening for Carrier Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia Genetic Screening for Carrier Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil Genetic Screening for Carrier Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil Genetic Screening for Carrier Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil Genetic Screening for Carrier Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina Genetic Screening for Carrier Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina Genetic Screening for Carrier Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina Genetic Screening for Carrier Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile Genetic Screening for Carrier Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile Genetic Screening for Carrier Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile Genetic Screening for Carrier Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia Genetic Screening for Carrier Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia Genetic Screening for Carrier Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia Genetic Screening for Carrier Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru Genetic Screening for Carrier Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru Genetic Screening for Carrier Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru Genetic Screening for Carrier Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia Genetic Screening for Carrier Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia Genetic Screening for Carrier Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Genetic Screening for Carrier Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel Genetic Screening for Carrier Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel Genetic Screening for Carrier Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel Genetic Screening for Carrier Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE Genetic Screening for Carrier Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE Genetic Screening for Carrier Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE Genetic Screening for Carrier Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey Genetic Screening for Carrier Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey Genetic Screening for Carrier Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey Genetic Screening for Carrier Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran Genetic Screening for Carrier Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran Genetic Screening for Carrier Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran Genetic Screening for Carrier Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt Genetic Screening for Carrier Diseases Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt Genetic Screening for Carrier Diseases Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt Genetic Screening for Carrier Diseases Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • NGS
  • Whole Exome Sequencing
  • Others
Applications
  • Couple
  • Individual
Companies covered
  • Thermo Fisher Scientific
  • Eurofins Scientific
  • Illumina
  • Invitae
  • MedGenome
  • Myriad Genetics
  • Roche
  • Natera
  • OPKO Health
  • 23andMe
  • bioMérieux
  • EKF Diagnostics
  • Gene by Gene (myDNA)
  • Fulgent Genetics
  • NxGen MDx
  • Sonic Genetics
  • My Baby
  • AncestryDNA
  • DiaSorin
  • Grifols
  • BGI Genomics
  • Chigene
  • Jiajian Medical Testing
  • Genesky
  • Berry Genomics
  • Weihansi Biomedical Technology
  • Annaroad

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Genetic Screening for Carrier Diseases Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Genetic Screening for Carrier Diseases Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Genetic Screening for Carrier Diseases Market Dynamics
  1. 2.1 Genetic Screening for Carrier Diseases Industry Trends
  2. 2.2 Genetic Screening for Carrier Diseases Industry Drivers
  3. 2.3 Genetic Screening for Carrier Diseases Industry Opportunities and Challenges
  4. 2.4 Genetic Screening for Carrier Diseases Industry Restraints
3 Genetic Screening for Carrier Diseases Market by Company
  1. 3.1 Global Genetic Screening for Carrier Diseases Company Revenue Ranking in 2025
  2. 3.2 Global Genetic Screening for Carrier Diseases Revenue by Company (2021-2026)
  3. 3.3 Global Genetic Screening for Carrier Diseases Company Ranking (2024-2026)
  4. 3.4 Global Genetic Screening for Carrier Diseases Company Manufacturing Base and Headquarters
  5. 3.5 Global Genetic Screening for Carrier Diseases Company Product Type and Application
  6. 3.6 Global Genetic Screening for Carrier Diseases Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Genetic Screening for Carrier Diseases Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Genetic Screening for Carrier Diseases Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Genetic Screening for Carrier Diseases Market by Type
  1. 4.1 Genetic Screening for Carrier Diseases Type Introduction
  2. 4.1.1 NGS
  3. 4.1.2 Whole Exome Sequencing
  4. 4.1.3 Others
  5. 4.2 Global Genetic Screening for Carrier Diseases Sales Value by Type
  6. 4.2.1 Global Genetic Screening for Carrier Diseases Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Genetic Screening for Carrier Diseases Sales Value by Type (2021-2032)
  8. 4.2.3 Global Genetic Screening for Carrier Diseases Sales Value Share by Type (2021-2032)
5 Genetic Screening for Carrier Diseases Market by Application
  1. 5.1 Genetic Screening for Carrier Diseases Application Introduction
  2. 5.1.1 Couple
  3. 5.1.2 Individual
  4. 5.2 Global Genetic Screening for Carrier Diseases Sales Value by Application
  5. 5.2.1 Global Genetic Screening for Carrier Diseases Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Genetic Screening for Carrier Diseases Sales Value by Application (2021-2032)
  7. 5.2.3 Global Genetic Screening for Carrier Diseases Sales Value Share by Application (2021-2032)
6 Genetic Screening for Carrier Diseases Regional Value Analysis
  1. 6.1 Global Genetic Screening for Carrier Diseases Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Genetic Screening for Carrier Diseases Sales Value by Region (2021-2032)
  3. 6.2.1 Global Genetic Screening for Carrier Diseases Sales Value by Region: 2021-2026
  4. 6.2.2 Global Genetic Screening for Carrier Diseases Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Genetic Screening for Carrier Diseases Sales Value (2021-2032)
  7. 6.3.2 North America Genetic Screening for Carrier Diseases Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Genetic Screening for Carrier Diseases Sales Value (2021-2032)
  10. 6.4.2 Europe Genetic Screening for Carrier Diseases Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Genetic Screening for Carrier Diseases Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Genetic Screening for Carrier Diseases Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Genetic Screening for Carrier Diseases Sales Value (2021-2032)
  16. 6.6.2 South America Genetic Screening for Carrier Diseases Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Genetic Screening for Carrier Diseases Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Genetic Screening for Carrier Diseases Sales Value Share by Country, 2025 VS 2032
7 Genetic Screening for Carrier Diseases Country-level Value Analysis
  1. 7.1 Global Genetic Screening for Carrier Diseases Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Genetic Screening for Carrier Diseases Sales Value by Country (2021-2032)
  3. 7.2.1 Global Genetic Screening for Carrier Diseases Sales Value by Country (2021-2026)
  4. 7.2.2 Global Genetic Screening for Carrier Diseases Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Genetic Screening for Carrier Diseases Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Genetic Screening for Carrier Diseases Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Genetic Screening for Carrier Diseases Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Genetic Screening for Carrier Diseases Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Genetic Screening for Carrier Diseases Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Genetic Screening for Carrier Diseases Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Genetic Screening for Carrier Diseases Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Genetic Screening for Carrier Diseases Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Genetic Screening for Carrier Diseases Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Genetic Screening for Carrier Diseases Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Genetic Screening for Carrier Diseases Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Genetic Screening for Carrier Diseases Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Genetic Screening for Carrier Diseases Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Genetic Screening for Carrier Diseases Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Genetic Screening for Carrier Diseases Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Genetic Screening for Carrier Diseases Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Genetic Screening for Carrier Diseases Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Genetic Screening for Carrier Diseases Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Genetic Screening for Carrier Diseases Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Genetic Screening for Carrier Diseases Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Genetic Screening for Carrier Diseases Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Genetic Screening for Carrier Diseases Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Genetic Screening for Carrier Diseases Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Genetic Screening for Carrier Diseases Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Genetic Screening for Carrier Diseases Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Genetic Screening for Carrier Diseases Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Genetic Screening for Carrier Diseases Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Genetic Screening for Carrier Diseases Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Genetic Screening for Carrier Diseases Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Genetic Screening for Carrier Diseases Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Genetic Screening for Carrier Diseases Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Genetic Screening for Carrier Diseases Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Genetic Screening for Carrier Diseases Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Genetic Screening for Carrier Diseases Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Genetic Screening for Carrier Diseases Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Genetic Screening for Carrier Diseases Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Genetic Screening for Carrier Diseases Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Genetic Screening for Carrier Diseases Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Genetic Screening for Carrier Diseases Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Genetic Screening for Carrier Diseases Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Genetic Screening for Carrier Diseases Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Genetic Screening for Carrier Diseases Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Genetic Screening for Carrier Diseases Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Genetic Screening for Carrier Diseases Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Genetic Screening for Carrier Diseases Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Genetic Screening for Carrier Diseases Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Genetic Screening for Carrier Diseases Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Genetic Screening for Carrier Diseases Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Genetic Screening for Carrier Diseases Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Genetic Screening for Carrier Diseases Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Genetic Screening for Carrier Diseases Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Genetic Screening for Carrier Diseases Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Genetic Screening for Carrier Diseases Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Genetic Screening for Carrier Diseases Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Genetic Screening for Carrier Diseases Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Genetic Screening for Carrier Diseases Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Genetic Screening for Carrier Diseases Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Genetic Screening for Carrier Diseases Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Genetic Screening for Carrier Diseases Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Genetic Screening for Carrier Diseases Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Genetic Screening for Carrier Diseases Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Genetic Screening for Carrier Diseases Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Genetic Screening for Carrier Diseases Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Genetic Screening for Carrier Diseases Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Genetic Screening for Carrier Diseases Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Genetic Screening for Carrier Diseases Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Genetic Screening for Carrier Diseases Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Genetic Screening for Carrier Diseases Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Genetic Screening for Carrier Diseases Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Genetic Screening for Carrier Diseases Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Genetic Screening for Carrier Diseases Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Genetic Screening for Carrier Diseases Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Genetic Screening for Carrier Diseases Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Genetic Screening for Carrier Diseases Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Genetic Screening for Carrier Diseases Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Genetic Screening for Carrier Diseases Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Genetic Screening for Carrier Diseases Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Genetic Screening for Carrier Diseases Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Genetic Screening for Carrier Diseases Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Genetic Screening for Carrier Diseases Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Genetic Screening for Carrier Diseases Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Genetic Screening for Carrier Diseases Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Genetic Screening for Carrier Diseases Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Genetic Screening for Carrier Diseases Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Thermo Fisher Scientific
  2. 8.1.1 Thermo Fisher Scientific Company Information
  3. 8.1.2 Thermo Fisher Scientific Business Overview
  4. 8.1.3 Thermo Fisher Scientific Genetic Screening for Carrier Diseases Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Thermo Fisher Scientific Genetic Screening for Carrier Diseases Product Portfolio
  6. 8.1.5 Thermo Fisher Scientific Recent Developments
  7. 8.2 Eurofins Scientific
  8. 8.2.1 Eurofins Scientific Company Information
  9. 8.2.2 Eurofins Scientific Business Overview
  10. 8.2.3 Eurofins Scientific Genetic Screening for Carrier Diseases Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Eurofins Scientific Genetic Screening for Carrier Diseases Product Portfolio
  12. 8.2.5 Eurofins Scientific Recent Developments
  13. 8.3 Illumina
  14. 8.3.1 Illumina Company Information
  15. 8.3.2 Illumina Business Overview
  16. 8.3.3 Illumina Genetic Screening for Carrier Diseases Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Illumina Genetic Screening for Carrier Diseases Product Portfolio
  18. 8.3.5 Illumina Recent Developments
  19. 8.4 Invitae
  20. 8.4.1 Invitae Company Information
  21. 8.4.2 Invitae Business Overview
  22. 8.4.3 Invitae Genetic Screening for Carrier Diseases Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Invitae Genetic Screening for Carrier Diseases Product Portfolio
  24. 8.4.5 Invitae Recent Developments
  25. 8.5 MedGenome
  26. 8.5.1 MedGenome Company Information
  27. 8.5.2 MedGenome Business Overview
  28. 8.5.3 MedGenome Genetic Screening for Carrier Diseases Revenue and Gross Margin (2021-2026)
  29. 8.5.4 MedGenome Genetic Screening for Carrier Diseases Product Portfolio
  30. 8.5.5 MedGenome Recent Developments
  31. 8.6 Myriad Genetics
  32. 8.6.1 Myriad Genetics Company Information
  33. 8.6.2 Myriad Genetics Business Overview
  34. 8.6.3 Myriad Genetics Genetic Screening for Carrier Diseases Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Myriad Genetics Genetic Screening for Carrier Diseases Product Portfolio
  36. 8.6.5 Myriad Genetics Recent Developments
  37. 8.7 Roche
  38. 8.7.1 Roche Company Information
  39. 8.7.2 Roche Business Overview
  40. 8.7.3 Roche Genetic Screening for Carrier Diseases Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Roche Genetic Screening for Carrier Diseases Product Portfolio
  42. 8.7.5 Roche Recent Developments
  43. 8.8 Natera
  44. 8.8.1 Natera Company Information
  45. 8.8.2 Natera Business Overview
  46. 8.8.3 Natera Genetic Screening for Carrier Diseases Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Natera Genetic Screening for Carrier Diseases Product Portfolio
  48. 8.8.5 Natera Recent Developments
  49. 8.9 OPKO Health
  50. 8.9.1 OPKO Health Company Information
  51. 8.9.2 OPKO Health Business Overview
  52. 8.9.3 OPKO Health Genetic Screening for Carrier Diseases Revenue and Gross Margin (2021-2026)
  53. 8.9.4 OPKO Health Genetic Screening for Carrier Diseases Product Portfolio
  54. 8.9.5 OPKO Health Recent Developments
  55. 8.10 23andMe
  56. 8.10.1 23andMe Company Information
  57. 8.10.2 23andMe Business Overview
  58. 8.10.3 23andMe Genetic Screening for Carrier Diseases Revenue and Gross Margin (2021-2026)
  59. 8.10.4 23andMe Genetic Screening for Carrier Diseases Product Portfolio
  60. 8.10.5 23andMe Recent Developments
  61. 8.11 bioMérieux
  62. 8.11.1 bioMérieux Company Information
  63. 8.11.2 bioMérieux Business Overview
  64. 8.11.3 bioMérieux Genetic Screening for Carrier Diseases Revenue and Gross Margin (2021-2026)
  65. 8.11.4 bioMérieux Genetic Screening for Carrier Diseases Product Portfolio
  66. 8.11.5 bioMérieux Recent Developments
  67. 8.12 EKF Diagnostics
  68. 8.12.1 EKF Diagnostics Company Information
  69. 8.12.2 EKF Diagnostics Business Overview
  70. 8.12.3 EKF Diagnostics Genetic Screening for Carrier Diseases Revenue and Gross Margin (2021-2026)
  71. 8.12.4 EKF Diagnostics Genetic Screening for Carrier Diseases Product Portfolio
  72. 8.12.5 EKF Diagnostics Recent Developments
  73. 8.13 Gene by Gene (myDNA)
  74. 8.13.1 Gene by Gene (myDNA) Company Information
  75. 8.13.2 Gene by Gene (myDNA) Business Overview
  76. 8.13.3 Gene by Gene (myDNA) Genetic Screening for Carrier Diseases Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Gene by Gene (myDNA) Genetic Screening for Carrier Diseases Product Portfolio
  78. 8.13.5 Gene by Gene (myDNA) Recent Developments
  79. 8.14 Fulgent Genetics
  80. 8.14.1 Fulgent Genetics Company Information
  81. 8.14.2 Fulgent Genetics Business Overview
  82. 8.14.3 Fulgent Genetics Genetic Screening for Carrier Diseases Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Fulgent Genetics Genetic Screening for Carrier Diseases Product Portfolio
  84. 8.14.5 Fulgent Genetics Recent Developments
  85. 8.15 NxGen MDx
  86. 8.15.1 NxGen MDx Company Information
  87. 8.15.2 NxGen MDx Business Overview
  88. 8.15.3 NxGen MDx Genetic Screening for Carrier Diseases Revenue and Gross Margin (2021-2026)
  89. 8.15.4 NxGen MDx Genetic Screening for Carrier Diseases Product Portfolio
  90. 8.15.5 NxGen MDx Recent Developments
  91. 8.16 Sonic Genetics
  92. 8.16.1 Sonic Genetics Company Information
  93. 8.16.2 Sonic Genetics Business Overview
  94. 8.16.3 Sonic Genetics Genetic Screening for Carrier Diseases Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Sonic Genetics Genetic Screening for Carrier Diseases Product Portfolio
  96. 8.16.5 Sonic Genetics Recent Developments
  97. 8.17 My Baby
  98. 8.17.1 My Baby Company Information
  99. 8.17.2 My Baby Business Overview
  100. 8.17.3 My Baby Genetic Screening for Carrier Diseases Revenue and Gross Margin (2021-2026)
  101. 8.17.4 My Baby Genetic Screening for Carrier Diseases Product Portfolio
  102. 8.17.5 My Baby Recent Developments
  103. 8.18 AncestryDNA
  104. 8.18.1 AncestryDNA Company Information
  105. 8.18.2 AncestryDNA Business Overview
  106. 8.18.3 AncestryDNA Genetic Screening for Carrier Diseases Revenue and Gross Margin (2021-2026)
  107. 8.18.4 AncestryDNA Genetic Screening for Carrier Diseases Product Portfolio
  108. 8.18.5 AncestryDNA Recent Developments
  109. 8.19 DiaSorin
  110. 8.19.1 DiaSorin Company Information
  111. 8.19.2 DiaSorin Business Overview
  112. 8.19.3 DiaSorin Genetic Screening for Carrier Diseases Revenue and Gross Margin (2021-2026)
  113. 8.19.4 DiaSorin Genetic Screening for Carrier Diseases Product Portfolio
  114. 8.19.5 DiaSorin Recent Developments
  115. 8.20 Grifols
  116. 8.20.1 Grifols Company Information
  117. 8.20.2 Grifols Business Overview
  118. 8.20.3 Grifols Genetic Screening for Carrier Diseases Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Grifols Genetic Screening for Carrier Diseases Product Portfolio
  120. 8.20.5 Grifols Recent Developments
  121. 8.21 BGI Genomics
  122. 8.21.1 BGI Genomics Company Information
  123. 8.21.2 BGI Genomics Business Overview
  124. 8.21.3 BGI Genomics Genetic Screening for Carrier Diseases Revenue and Gross Margin (2021-2026)
  125. 8.21.4 BGI Genomics Genetic Screening for Carrier Diseases Product Portfolio
  126. 8.21.5 BGI Genomics Recent Developments
  127. 8.22 Chigene
  128. 8.22.1 Chigene Company Information
  129. 8.22.2 Chigene Business Overview
  130. 8.22.3 Chigene Genetic Screening for Carrier Diseases Revenue and Gross Margin (2021-2026)
  131. 8.22.4 Chigene Genetic Screening for Carrier Diseases Product Portfolio
  132. 8.22.5 Chigene Recent Developments
  133. 8.23 Jiajian Medical Testing
  134. 8.23.1 Jiajian Medical Testing Company Information
  135. 8.23.2 Jiajian Medical Testing Business Overview
  136. 8.23.3 Jiajian Medical Testing Genetic Screening for Carrier Diseases Revenue and Gross Margin (2021-2026)
  137. 8.23.4 Jiajian Medical Testing Genetic Screening for Carrier Diseases Product Portfolio
  138. 8.23.5 Jiajian Medical Testing Recent Developments
  139. 8.24 Genesky
  140. 8.24.1 Genesky Company Information
  141. 8.24.2 Genesky Business Overview
  142. 8.24.3 Genesky Genetic Screening for Carrier Diseases Revenue and Gross Margin (2021-2026)
  143. 8.24.4 Genesky Genetic Screening for Carrier Diseases Product Portfolio
  144. 8.24.5 Genesky Recent Developments
  145. 8.25 Berry Genomics
  146. 8.25.1 Berry Genomics Company Information
  147. 8.25.2 Berry Genomics Business Overview
  148. 8.25.3 Berry Genomics Genetic Screening for Carrier Diseases Revenue and Gross Margin (2021-2026)
  149. 8.25.4 Berry Genomics Genetic Screening for Carrier Diseases Product Portfolio
  150. 8.25.5 Berry Genomics Recent Developments
  151. 8.26 Weihansi Biomedical Technology
  152. 8.26.1 Weihansi Biomedical Technology Company Information
  153. 8.26.2 Weihansi Biomedical Technology Business Overview
  154. 8.26.3 Weihansi Biomedical Technology Genetic Screening for Carrier Diseases Revenue and Gross Margin (2021-2026)
  155. 8.26.4 Weihansi Biomedical Technology Genetic Screening for Carrier Diseases Product Portfolio
  156. 8.26.5 Weihansi Biomedical Technology Recent Developments
  157. 8.27 Annaroad
  158. 8.27.1 Annaroad Company Information
  159. 8.27.2 Annaroad Business Overview
  160. 8.27.3 Annaroad Genetic Screening for Carrier Diseases Revenue and Gross Margin (2021-2026)
  161. 8.27.4 Annaroad Genetic Screening for Carrier Diseases Product Portfolio
  162. 8.27.5 Annaroad Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst